STOP-AUST: The Spot Sign And Tranexamic Acid On Preventing Intracerebral Haemorrhage Growth – AUStralasia Trial
Funder
National Health and Medical Research Council
Funding Amount
$764,621.00
Summary
The STOP-AUST study is a randomized controlled trial with the aim of testing whether the medication tranexamic acid when given early within 4.5 hours of symptom onset is superior to standard care alone in stopping intracerebral haemorrhage (ICH, a bleeding into the brain) growth. Total 100 to 150 patients will be enrolled into the study.
Acute Stroke Care: Rapid Unblocking Of Vessels, Mending Ruptures, And Recovery
Funder
National Health and Medical Research Council
Funding Amount
$204,399.00
Summary
During this fellowship, A/Prof Meretoja will 1) use blood biomarkers, telemedicine, and ambulance-based imaging to streamline the time-critical therapy of stroke thrombolysis, 2) run a pharmaceutical trial of the drug tranexamic acid in intracerebral haemorrhage, and 3) use stroke registries in Australia and Finland to disseminate best practices in stroke care pathways.
Enhanced Control Of Hypertension And Thrombolysis In Stroke Study (STAY ENCHANTED)
Funder
National Health and Medical Research Council
Funding Amount
$2,437,384.00
Summary
"Clot busting" treatment is the only approved medical treatment for the commonest type of stroke, ischaemic stroke. However, uptake of treatment remains poor, mainly due to the known major risk of bleeding in the brain. STAY ENCHANTED is an international clinical trial to investigate whether "clot-busting" can be made safer using a lower dose and/or immediate blood pressure lowering. A safer more effective regime could have a major global health impact.
The Effect Of Anti-fibrinolytic Drugs On Blood-brain Barrier Integrity And The Immune Response In Traumatic Brain Injury
Funder
National Health and Medical Research Council
Funding Amount
$870,476.00
Summary
This project aims to determine how a well known anti-fibrinolytic drug can improve the immune response and reduced blood brain barrier disruption following traumatic brain injury. We will also be testing additional drugs we have developed as well as a novel drug delivery system that better targets drugs to the damaged brain.
This Australian-led, investigator initiated and conducted study, is the first and only large scale clinical trial designed to assess the balance of potential benefits and risks of early rapid blood pressure lowering in intracerebral haemorrhage stroke, a disease in which there is still no convincing evidence of benefit from any medical treatment, where the role of surgery remains controversial, and from which the chances of surviving has failed to improve in recent decades.
10-year Outcome After Stroke: Final Follow-up For Survival, Stroke Recurrence, Functional Ability And Costs
Funder
National Health and Medical Research Council
Funding Amount
$51,475.00
Summary
Stroke is common, occurring in approximately 50,000 Australians each year. About a third of people with stroke die within the first 12 months but we do not know how many survive or how well they manage in the longer term. We aim to interview 10-year survivors of stroke to assess how much help they need to undertake everyday activities, and how much the stroke is costing the Australian community. This information will help us in planning the health care needs for stroke patients in future years.
Long-term Outcome After Stroke: Survival, Stroke Recurrence, Functional Ability And Costs.
Funder
National Health and Medical Research Council
Funding Amount
$649,971.00
Summary
Stroke is the third most common cause of death in Australia, and is more common in the older age groups. Because the population most at risk of developing stroke is growing faster than the rest of the population, it is likely that there will be a large increase in the number of strokes occurring in coming years. At 1 year after stroke about one-third of patients have died, a third remain severely disabled and a third recover with minimal disability. In Australia, there is no information on outco ....Stroke is the third most common cause of death in Australia, and is more common in the older age groups. Because the population most at risk of developing stroke is growing faster than the rest of the population, it is likely that there will be a large increase in the number of strokes occurring in coming years. At 1 year after stroke about one-third of patients have died, a third remain severely disabled and a third recover with minimal disability. In Australia, there is no information on outcome beyond 5 years. It is thought that at 10 years after stroke about 70% of patients will have died, and a further 5-10% will have had another nonfatal stroke. The aim of this study is to assess the long-term outcome of patients with stroke. These will include measures of survival, stroke recurrence, and ability to perform usual daily activities. The use of health care and community resources and the associated costs of this will also be assessed. Information on survival patterns, stroke recurrence, disability and costs will be of great value for health service planning. Such information will also be useful to patients, their families, and medical staff who treat these patients.Read moreRead less
LONG TERM FUNCTIONAL ABILITY AND COSTS OF STROKE SUBTYPES.
Funder
National Health and Medical Research Council
Funding Amount
$270,604.00
Summary
Stroke is the third most common cause of death in Australia, and is more common in the older age groups. Because the population most at risk of developing stroke is growing faster than the rest of the population, it is likely that there will be a large increase in the number of strokes occurring in coming years. At 1 year after stroke about one-third of patients have died, a third remain severely disabled and a third recover with minimal disability. In Australia, there is little information on o ....Stroke is the third most common cause of death in Australia, and is more common in the older age groups. Because the population most at risk of developing stroke is growing faster than the rest of the population, it is likely that there will be a large increase in the number of strokes occurring in coming years. At 1 year after stroke about one-third of patients have died, a third remain severely disabled and a third recover with minimal disability. In Australia, there is little information on outcome beyond 1 year. It is thought that at 5 years after stroke about 55% of patients will die, and a further 10% will have another nonfatal stroke. Stroke is estimated to cost the community in excess of $1 billion a year. Little is known about the long-term costs of stroke to survivors and their relatives. These costs are likely to be substantial, and are likely to include costs related to hospitalisations, outpatient visits, general practitioner visits, medications, aids and community services. It is also likely that substantial informal care is provided by relatives and friends (e.g. assistance with shopping and personal care). The aim of this study is to assess the long-term outcome of patients with stroke. These will include measures of survival, stroke recurrence, and ability to perform usual daily activities. In addition, we aim to determine the long-term use of health care and community resources and the costs incurred by patients, their carers, and the community. Information on survival patterns, stroke recurrence and disability will provide information of great value for health service planning. Such information will also be useful to patients, their families, and medical staff who treat these patients. Information on the costs of stroke will provide the only information about the patterns of long-term health care and community resource use among stroke patients in Australia. This information will be useful for health service planning.Read moreRead less